Dec

30

Industrial Nanotech

Filed Under Nanotechnology | Leave a Comment

Industrial Nanotech, Inc. (Symbol: INTK), a Delaware corporation, is founded in 2004 by the founders: current CEO, Stuart Burchill, and President, Laurie Scherock, MBA.

It is important to remember that nanotechnology as an industry is only as good as its ability to assist other industries, and ultimately, consumers. It does not exist in a vacuum. Suppose the timber industry chopped down trees, processed wood, and then simply stockpiled the raw material. The timber industry is only as valuable as what it adds to consumers’ ability to build houses, make furniture, use paper products, etc. It is the same with nanotechnology.
So, Industrial Nanotech was formed with the goal to develop end-user products.

What is Nanotechnology?

Nanotechnology is the manipulation of cell and atomic structure in materials that are no larger than a billionth of a meter in size.

“Science and technology on the scale of a nanometer – one billionth of a meter – is revolutionary. Nanotechnology could change the way almost everything is designed and made, from automobile tires to vaccines to objects not yet imagined.”
The Company’s target market is industrial entities that require a coating that provides insulation without causing, and even preventing, Corrosion-under-Insulation. Industrial Nanotech’s initial focus has been on the following markets:

Large manufacturing, processing and utility companies – petroleum refineries, food processing plants, power plants, etc.;

Residential and commercial construction industries – air conditioning duct manufacturers, metal building component manufacturers, general contractors, etc.;

Ship building and maintenance industry – commercial fishing fleets, supertankers, etc.;

Military – tanks, ships, aircraft, etc; and

Central to the Company’s sales strategy is its growing global distribution network – which has now reached 18 distributors and an additional five in the final stages of coming aboard. Industrial Nanotech started accepting applications in April 2004 after defining a global strategy and lengthy process of designing a distributorship program that is congruent with expansion plans globally, and of primary importance, protects the Company’s proprietary information, products, and intellectual property. Individuals and companies expressing an interest in obtaining distribution rights are pre-qualified, and minimum inventory and sales quotas are required to maintain their exclusive, geographical distribution rights.

Above is their stock performance in the past 6 months.

If Nanotechnology, the manipulation of matter at the atomic level, at maturity achieves even a fraction of its promise, it will force the reassessment of global markets and economies and industries on a scale never experienced before in human history. Imagine the emergence of a nanochip that tomorrow would deliver over 50 gigahertz of speed with the processing power of ten supercomputers for the price of a quartz watch and smaller than a key chain. What might the economic impact on the computer industry be overnight?

Source: industrial-nanotech.com

Quote of the Day:
Risk comes from not knowing what you’re doing. – Warren Buffett

  • Share/Bookmark

Dec

8

Investing in Treatments for Heart Disease

Filed Under Medical Equipment & Supplies | Leave a Comment

Heart disease is, unfortunately, a growth industry, Three percent of baby boomers currently have heart disease and that number is expected to grow 10-15 percent within that demographic over the next 10 years. That’s more than 500,000 new cases annually for what remains the number one killer in the US of both men and women. Healthcare costs associated with heart disease already exceed $23 billion annually.

MIV Therapeutics Inc. (Symbol: MIVT) is an advanced stage, research and development company pursuing the commercialization of the next generation of fully biocompatible coatings for stents and other medical devices with the intent of providing healing solutions for cardiovascular disease and other conditions. In collaboration with the University of British Columbia (UBC), the Company has developed unique coating technologies that utilize Hydroxyapatite (HAp) for application on medical devices and drug delivery systems.

MIVT has a strategic alliance with the University of British Columbia (UBC), where it has licensed from the university worldwide rights to technologies for coating stents and other medical devices with HAp. This coating enhances the biocompatibility of implanted devices since it is a material that is found in the body as the main constituent of bone.

MIVT’s technology is considered to be suitable for broad applications in cardiovascular and non-vascular drug/device combination products. The Company’s goal is to continue on its path of success and diversify its portfolio to capitalize on these potential applications, accessing the $200 billion market of combination drug/device products.

MIVT’s current product portfolio encompasses the following preclinical development projects:

  • HAp-nano-film coating technology. The Company’s lead product in development is an HAp-coated coronary stent with a nano-film coating. HAp is naturally found in bone and tooth enamel and is rapidly integrated into the human body. As such, it may inhibit a variety of adverse and inflammatory reactions and potentially help reduce restenosis, a recurrence of CAD following angioplasty. It is also believed that HAp-coated cardiovascular stents will not trigger late adverse thrombogenic reactions.
  • Drug-eluting stents. The Company is expected to enter the drug-eluting stent market by using a thicker coating of HAp loaded with a suitable drug, i.e. anti-inflammatory. The technology has applications in cardiovascular and non-cardiovascular drug/device combination products, including peripheral stents, biodegradable implants, gene therapy, and delivery systems for release of chemotherapeutic agents.

Recently there was a spike in the volume which, I must say, really intrigued me. The price has jumped up from $0.35/share to around $0.55/share. It went down a bit, then it shot up to $0.60/share. Could it be because Ernest C. Schloter, a senior analyst with Investrend affiliate SISM Research and a four star analyst according to StarMine, has reiterated his “Buy/4″ Rating and $2.50 12-month Target Valuation for MIV Therapeutics, Inc. in a Research Note?

Here are some of the comments which I have heard about them:

“The drug-eluting stent market grew from zero to $5.3 billion in three years and has captured 85% of the US stent market. To date, more than nine million DES devices have been inserted. In 2005, about 1.5 million patients were implanted with drug-eluting stents in the US alone…”

“Despite a stock price increase of more than 50% since last Wednesday, in our view, MIVT, at a market cap of only $35 million, is still massively undervalued… MIV Therapeutics is paying SISM Research $2,250 per month over a two-year period solely to ensure independent coverage.”

Hmm pretty interesting, don’t you think? I’m always fond of biotech stocks, regardless of whether they’re traded at a ridiculously low price or amazingly high price. This one happens to be traded a ridiculously low price and even a lot of people think of this one is undervalued. Well…We’ll see what’s going to happen with this one in the next 3-6 months.

Source: mivtherapeutics.com

Quote of the Day:
Foreign Aid: Taxing poor people in rich countries for the benefit of rich people in poor countries. – Bernard Rosenberg

  • Share/Bookmark

ss_blog_claim=15d8108b540c7f0a9f388810cf5ad68f ss_blog_claim=15d8108b540c7f0a9f388810cf5ad68f